This is a preview of subscription content, log in via an institution to check access.
Reference
Arbel R, et al. Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clinical Drug Investigation : 24 May 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00929-z
Rights and permissions
About this article
Cite this article
Cost advantage with empagliflozin for preventing heart failure events in T2DM. PharmacoEcon Outcomes News 854, 11 (2020). https://doi.org/10.1007/s40274-020-6841-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6841-2